

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.3. Antiretrovirals > Protease inhibitors](#)

EMLc

Codes ATC: [J05AE01](#)

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Code ICD11: <a href="#">1C62.Z</a>
INN	Saquinavir
Type de médicament	Chemical agent
Type de liste	Liste de base (EML) (EMLc)
Formulations	Oral > Solid: 200 mg ; 500 mg
Historique des statuts LME	Ajouté pour la première fois en 2002 ( <a href="#">TRS 914</a> ) Modifié en 2007 ( <a href="#">TRS 950</a> ) Modifié en 2009 ( <a href="#">TRS 958</a> ) Retiré en 2017 ( <a href="#">TRS 1006</a> )
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Restriction de poids	> 25 kg
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a>
Wikipédia	<a href="#">Saquinavir</a>
DrugBank	<a href="#">Saquinavir</a>

## Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended the deletion of saquinavir from the Model Lists, noting that that clinical use of the protease inhibitor saquinavir has declined over time with the introduction of newer antiretroviral agents with lower pill burden, similar or greater effectiveness and lower risk of toxicity. Unlike other protease inhibitors, saquinavir is associated with QT prolongation and a requirement for ECG monitoring. Numerous alternative protease inhibitors (with and without ritonavir) remain listed on the EML.

